Hyperhomocysteinaemia and endothelial dysfunction in dialysis patients: what should be treated first?
Righetti
Marco
M
D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D007674:Kidney Diseases / Q000503:physiopathology / Q000628:therapy; D002955:Leucovorin / Q000627:therapeutic use; D006435:Renal Dialysis; D020521:Stroke / Q000503:physiopathology / Q000517:prevention & control; D013763:Tetrahydrofolates / Q000627:therapeutic use; D014805:Vitamin B 12 / Q000627:therapeutic use; D025101:Vitamin B 6 / Q000627:therapeutic use
D013763:Tetrahydrofolates; D025101:Vitamin B 6; D014805:Vitamin B 12; D002955:Leucovorin; C005984:5-methyltetrahydrofolate